Angiodynamics, Inc. ((ANGO)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Angiodynamics, Inc. is conducting a clinical trial titled ‘Randomized Controlled Trial of the Auryon Atherectomy System Used in Combination With Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone Treating Infrapopliteal Lesions in Subjects With Critical Limb Ischemia.’ The study aims to determine if the Auryon Atherectomy System combined with balloon angioplasty is more effective than balloon angioplasty alone in preventing death, amputation, revascularization, and improving patency in patients with critical limb ischemia.
Intervention/Treatment: The trial tests the Auryon Atherectomy System, a device composed of a laser and catheter, used alongside balloon angioplasty. This combination is compared to the use of balloon angioplasty alone to assess its effectiveness in treating lower limb blockages.
Study Design: This Phase 4 interventional study is randomized with a parallel assignment. There is no masking involved, and the primary purpose is treatment. Participants are allocated to either the experimental group receiving the Auryon Atherectomy System with balloon angioplasty or the active comparator group receiving only balloon angioplasty.
Study Timeline: The study began on January 7, 2025, with the latest update submitted on July 23, 2025. These dates are crucial as they mark the progression and current status of the trial, which is still recruiting participants.
Market Implications: This study could significantly impact Angiodynamics’ stock performance and investor sentiment, especially if the Auryon Atherectomy System proves more effective. Success in this trial could position Angiodynamics favorably against competitors in the peripheral arterial disease treatment market, potentially leading to increased market share and revenue.
The study is ongoing, with further details available on the ClinicalTrials portal.